tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Simulations Plus Announces Fiscal 2025 Results and 2026 Guidance

Story Highlights
Simulations Plus Announces Fiscal 2025 Results and 2026 Guidance

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Simulations Plus ( (SLP) ) has shared an announcement.

On October 22, 2025, Simulations Plus announced its preliminary fiscal year 2025 results and issued guidance for fiscal year 2026. The company reported a revenue of $79.1 million for fiscal 2025, with a 13% growth, and provided a revenue guidance of $79 to $82 million for fiscal 2026. Despite challenging market conditions, the company expects to meet its revised fiscal 2025 guidance. They also unveiled a new product vision to enhance software delivery and AI capabilities, marking the launch of GastroPlus® X.2 on the S+ Cloud as a significant step in their cloud and AI strategy.

The most recent analyst rating on (SLP) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.

Spark’s Take on SLP Stock

According to Spark, TipRanks’ AI Analyst, SLP is a Neutral.

Simulations Plus has a solid financial foundation with strong revenue growth and cash flow management. However, recent profitability issues and a negative P/E ratio raise concerns about valuation. The technical analysis suggests mixed momentum, while the earnings call reflects both growth potential and significant challenges. Strategic initiatives may improve future performance, but current market headwinds and operational hurdles weigh on the overall outlook.

To see Spark’s full report on SLP stock, click here.

More about Simulations Plus

Simulations Plus, Inc. is a leading provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Their solutions integrate artificial intelligence and machine learning, along with various pharmacokinetic and pharmacodynamic modeling approaches, and are utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.

Average Trading Volume: 516,583

Technical Sentiment Signal: Sell

Current Market Cap: $323M

For an in-depth examination of SLP stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1